Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05798611
Other study ID # ART0380C004
Secondary ID 2023-504153-12
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 6, 2023
Est. completion date March 2025

Study information

Verified date January 2024
Source Artios Pharma Ltd
Contact Artios Pharma
Phone +44 (0)1223 867 900
Email info@artios.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).


Description:

ART0380 is being developed as an oral anti-cancer agent for the treatment of patients with cancers that have defects in deoxyribonucleic acid (DNA) repair. The study will recruit selected patients with advanced or metastatic solid tumors, specifically: - Patients with persistent or recurrent endometrial cancer (EC) - Patients with advanced or metastatic solid tumors of any histology Above patients will be randomized in a 1:1 ratio to one of two dose regimens of ART0380. Safety will be evaluated on a quarterly basis, at a minimum. Patients may continue to receive ART0380 as long as they are continuing to derive benefit from treatment or until disease progression, withdrawal of consent, or until they experience unacceptable drug-related toxicity.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who have discontinued all previous treatments for cancer for at least 21 days or 5 half-lives (not including palliative radiotherapy at focal sites), whichever is shorter. Palliative radiotherapy must have completed 1 week prior to start of study treatment. - Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, neuropathy, and alopecia, which must have resolved to Grade =2). - Have adequate organ function. - Patients of childbearing potential and patients with partners of childbearing potential are required to use highly effective contraception. - Have an estimated life expectancy of =12 weeks, in the judgment of the investigator. - Performance status of 0-1 on the Eastern Cooperative Oncology Group scale. - Have a non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available. Inclusion Criteria specific to each Arm Inclusion Criteria for Arm 1 [ART0380 monotherapy (endometrial cancer patients)] - Persistent or recurrent EC with biological selection. - Patients should have received taxane/platinum chemotherapy unless contraindicated. - Measurable disease. Inclusion Criteria for Arm 2 [ART0380 monotherapy (solid tumors patients)] - Advanced or metastatic solid cancers of any histology with biological selection. - If a Programmed cell death protein-1 /Programmed death-ligand-1 inhibitor (e.g., pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study. - Radiologically evaluable disease. Exclusion Criteria: - Patients who are pregnant. - Prior treatment with an inhibitor of ATR, WEE1, checkpoint kinase 1 or PKMYT1. - Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to the protocol. - Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic). - Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression. - Have any major gastrointestinal issues that could impact absorption of ART0380. - Have a history of allergy or hypersensitivity to study drug components. - Have a significant bleeding disorder or vasculitis or had a Grade =3 bleeding episode within 12 weeks prior to enrollment. - Patients receiving potent inhibitors and inducers of CYP3A4 or CYP3A4 substrates which have a narrow therapeutic range or CYP3A4 sensitive substrates within 2 weeks before the first dose of study treatment will be excluded. - Patients receiving the following within 2 weeks of the first dose will be excluded from study treatment. 1. P-glycoprotein or breast cancer resistance protein (BCRP) inhibitors 2. Statins - Patients who plan to father a child while in the study or within 16 weeks (5 months in France) after the last administration of study treatment.

Study Design


Intervention

Drug:
ART0380
Randomized patients will orally receive ART0380.

Locations

Country Name City State
France Hopital Lyon Sud Pierre-Benite NAP
United States Dana Farber Cancer Center Boston Massachusetts
United States The University of Chicago Chicago Illinois
United States Northwell Health R.J. Zuckerberg Cancer Center Lake Success New York
United States University of California Los Angeles (UCLA) Los Angeles California
United States Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology New York New York
United States University of Oklahoma/Sarah Cannon Research Institute Oklahoma City Oklahoma
United States Western Pennsylvania Hospital Pittsburgh Pennsylvania
United States Women and Infants Hospital Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
Artios Pharma Ltd

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) Objective Response Rate (ORR) is defined as the proportion of patients with a complete response (CR) or partial response (PR) to treatment according to Response evaluation criteria in solid tumors (RECIST v1.1). Until disease progression (Every 6 weeks from randomization Upto 2 Years)
Secondary Number of patients with adverse events To assess the safety and tolerability of ART0380 in patients with solid tumors. From Cycle 1 (each Cycle is 21-day) Day 1 until 30-day follow-up visit (Upto 2 Years)
Secondary Progression free survival (PFS) The PFS is defined as the time from randomization until the earliest objective disease progression defined by RECIST v1.1 or Prostate Cancer Working Group 3 (PCWG-3) (for patients with prostate cancer in Arm 2) or death by any cause in the absence of progression, regardless of whether the patient withdraws from study medication or receives another anti-cancer therapy prior to progression. Screening (=28 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)
Secondary Best overall response (BOR) The best overall response is the best response (complete response, and partial response) recorded from the date of randomization for each patient until the progression or censoring date in the absence of progression. Screening (=28 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)
Secondary Disease control rate (DCR) To further explore the efficacy of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms. Screening (=28 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)
Secondary Duration of response (DOR) The DOR will be defined for patients with a BOR of CR/PR, as the time from the date of first documented response until date of documented progression (by RECIST v1.1) or death in the absence of disease progression. Screening (=28 days) Until disease progression or death (Every 6 weeks from randomization Upto 2 Years)
Secondary Change in tumor size The best percentage change in tumor size from baseline will be determined for each patient, ie, the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction. Screening (=28 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)
Secondary Overall survival (OS) The OS is defined as the time from the randomization until death due to any cause. Screening (=28 days) Until overall survival follow-up (Every 12 weeks until data cut-off)
Secondary Maximum plasma concentration (Cmax) To determine the Cmax of ART0380 following single oral dosing of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms. Pre-dose Cycle 1 day 1, 2, 15, 16, 17, 18, Cycle 2 day 1, Cycle 3 day 1 Upto 2 Years (Each Cycle is 21-days)
Secondary Half life (t1/2) To determine the t1/2 of ART0380 following single oral dosing of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms. Pre-dose Cycle 1 days 1, 2, 15, 16, 17, 18, Cycle 2 day 1, Cycle 3 day 1 Upto 2 Years (Each Cycle is 21-days)
Secondary Area under the plasma concentration-time curve from zero to infinity (AUC0-inf) To determine the AUC0-inf of ART0380 following single oral dosing of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms. Pre-dose Cycle 1 days 1, 2, 15, 16, 17, 18, Cycle 2 day 1, Cycle 3 day 1 Upto 2 Years (Each Cycle is 21-days)
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05515185 - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors Early Phase 1
Completed NCT05508100 - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors Phase 1
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT02836600 - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04890613 - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Completed NCT04108676 - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects Phase 1
Recruiting NCT05076396 - PM14 Administered Intravenously to Patients With Advanced Solid Tumors Phase 1
Recruiting NCT06008366 - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06054932 - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors Phase 1
Recruiting NCT04825392 - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06365918 - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Phase 1
Recruiting NCT05461287 - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05569057 - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT05443126 - A Study of EP0031 in Patients With Advanced RET-altered Malignancies Phase 1/Phase 2
Active, not recruiting NCT04592653 - Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) Phase 1/Phase 2